

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

ANNOUNCEMENT PURSUANT TO RULE 13.19 OF THE LISTING RULES

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.19 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 30 June 2025 and 30 September 2025 in relation to the quarterly updates on the implementation of the action plan to resolve the audit qualification (the “**Quarterly Updates**”).

On 12 December 2022, Shanxi Touyun Biotechnology Co., Ltd.* (the “**Borrower**”), a wholly-owned subsidiary of the Company, entered into a loan agreement (the “**Loan Agreement**”) with a lender (the “**Lender**”) for a loan with a principal amount of RMB90 million (the “**Loan**”), with a maturity date of 11 December 2025. As of 11 December 2025, being the maturity date of the Loan Agreement, the Borrower has not yet repaid the Loan. As at the date of this announcement, together with the overdue loan of RMB60 million as previously disclosed in the Quarterly Updates, the aggregated overdue loan amount payable to the Lender is RMB150 million (the “**Outstanding Loans**”).

* For translation purpose only

The management of the Group is currently in negotiations with the Lender regarding partial repayment and a further extension of the repayment date for the Outstanding Loans. The Company will make further announcement(s) as and when necessary or appropriate if there are any material developments concerning the Outstanding Loans. The non-payment of the Outstanding Loans could have a negative impact on the Group's operations.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 11 December 2025

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen